Advancing the Future of Reflux Care
The Reflux Company is a medical device company dedicated to improving the diagnosis and treatment of gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR). Our mission is to provide physicians with clinically validated technologies that enable earlier diagnosis, more effective treatment, and better outcomes for millions of patients worldwide.
Our portfolio spans the continuum of reflux care—from objective diagnostics to minimally invasive therapies and non-surgical treatment options—making The Reflux Company one of the few organizations focused exclusively on comprehensive reflux management.
Our Business
The Reflux Company is building a diversified medical technology platform through the commercialization and strategic acquisition of innovative reflux technologies.
Our current portfolio includes:
• Restech Dx-pH® – Objective oropharyngeal pH monitoring for suspected laryngopharyngeal reflux.
• Stretta® – A minimally invasive radiofrequency therapy for GERD.
• Reflux Band® – An external upper esophageal sphincter compression device for reflux management.
• PepsinCheck™ by Peptest® – A rapid salivary pepsin test supporting reflux diagnosis.
Together, these technologies allow physicians to diagnose reflux more accurately and offer personalized treatment options across a broad spectrum of patients.
Partner With Us
We welcome discussions with:
• Investors
• Strategic Partners
• Distribution Partners
• Healthcare Providers
Together, we can advance the standard of care for reflux disease worldwide.
Development Team